Genomic Surveillance & Sequencing Market Set to Reach $74.1 Billion by 2036 as Lower Costs and Precision Medicine Accelerate Adoption

The global genomic surveillance/sequencing market is entering a period of rapid expansion as sequencing moves from specialized research laboratories into routine clinical, diagnostic, pharmaceutical, biotechnology, and public-health workflows. The market was valued at USD 13.8 billion in 2025 and is projected to reach USD 74.1 billion by 2036, expanding at a 16.5% CAGR from 2026 to 2036.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86982

Genomic sequencing enables researchers and healthcare providers to characterize genetic information at increasingly high speed and accuracy. Its applications now extend across oncology, infectious diseases, rare genetic disorders, reproductive health, population genomics, agriculture, environmental research, and forensic science.

Market Overview

The market's expansion is being supported by a combination of technological progress and growing healthcare demand. Consumables and reagents accounted for 48.9% of market revenue in 2025, reflecting the recurring nature of sequencing workflows. Unlike instruments, which represent periodic capital expenditure, reagents, flow cells, library-preparation kits, and other consumables are required for repeated sequencing runs.

North America held the largest regional revenue share at 46.3% in 2025, supported by strong research infrastructure, healthcare spending, biotechnology activity, and investment in genomic medicine.

The competitive environment includes established short-read sequencing companies, long-read technology providers, diagnostic companies, reagent manufacturers, bioinformatics firms, and sequencing-service organizations.

Key Drivers of Market Growth

Declining Sequencing Costs

Falling sequencing costs remain one of the strongest structural growth factors. Higher throughput, automation, improved reagent utilization, and more efficient workflows are reducing the cost of generating genomic information.

The cost decline is also expanding the addressable customer base. Hospitals, diagnostic laboratories, biotechnology companies, and public-health agencies can increasingly incorporate sequencing into workflows that previously depended on conventional testing or were limited to major research institutions.

Long-read sequencing economics are also improving. PacBio reported in 2026 that its SPRQ-Nx chemistry can reduce sequencing costs substantially, with the potential for approximately USD 300 per human genome at scale.

Rising Cancer and Genetic Disease Burden

Cancer and genetic disorders are strengthening demand for genomic testing. Tumor profiling, companion diagnostics, liquid biopsy, inherited-disease testing, and molecular characterization are creating opportunities for sequencing-based diagnostics.

Rare disease diagnosis is another important application because sequencing can identify variants that conventional diagnostic approaches may miss. Reproductive health applications, including carrier screening and non-invasive prenatal testing, are also expanding genomic testing volumes.

Key Players and Industry Leaders

The competitive landscape includes Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, Pacific Biosciences, Oxford Nanopore Technologies, BGI Genomics, QIAGEN, Agilent Technologies, Revvity, Danaher, bioMérieux, Bio-Rad Laboratories, Eurofins Scientific, Guardant Health, Natera, 10x Genomics, Element Biosciences, and Singular Genomics, among others.

Illumina continues to focus on scalable genomic workflows. In February 2026, the company launched TruPath Genome, designed to simplify whole-genome workflows and improve access to challenging genomic regions. The company states that the solution can generate up to 16 genomes per day.

Roche entered a new phase of sequencing-platform development with the June 2026 launch of AXELIOS 1, based on sequencing-by-expansion technology. Roche says the research-use platform supports same-day whole-genome sequencing and integrates dedicated analysis capabilities.

Key Trends for the Future

Several trends are expected to shape the market through 2036. First, sequencing is moving closer to routine clinical use as workflows become simpler and more automated. Second, long-read sequencing is gaining attention for structural variants, complex genomic regions, phasing, and rare disease applications.

Real-time sequencing is another emerging trend, particularly for infectious-disease surveillance and outbreak response. Faster sequencing-to-result workflows can support more timely genomic characterization of pathogens.

Artificial intelligence is also becoming increasingly important in genomic data analysis. AI-based algorithms can help process large sequencing datasets, identify variants, improve interpretation, and integrate genomic information with other biological data.

Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/genomic-surveillance-sequencing-market.html

New Opportunities and Challenges

Emerging economies represent a significant opportunity because sequencing penetration remains below that of mature markets while healthcare infrastructure and biotechnology ecosystems are expanding.

Population genomics programs, national sequencing initiatives, local diagnostic laboratories, and pharmaceutical research are creating new demand across Asia Pacific, Latin America, the Middle East, and Africa. India, China, and other high-population markets offer substantial potential because of their large and genetically diverse populations.

However, challenges remain. High initial instrument costs, data-storage requirements, shortage of skilled genomic professionals, regulatory complexity, reimbursement limitations, and privacy concerns can slow adoption. Laboratories also need reliable bioinformatics infrastructure to convert large genomic datasets into clinically useful information.

Market Trends & Innovations

Innovation is increasingly focused on improving the complete sequencing workflow rather than only increasing read accuracy. Simplified sample preparation, automated library preparation, reusable consumables, faster sequencing, integrated analytics, and cloud-based interpretation are becoming important competitive factors.

Long-read technologies are particularly significant because they can reveal structural variation and complex genomic regions that may be difficult to characterize using short reads. PacBio's 2026 commercial availability of SPRQ-Nx illustrates the industry's focus on lowering long-read sequencing costs while maintaining high-fidelity data.

Roche's AXELIOS 1 also highlights the push toward high-speed, scalable sequencing architectures and near-real-time analysis.

Future Outlook

The genomic surveillance/sequencing market is expected to maintain strong growth through 2036 as sequencing becomes faster, more affordable, and more integrated into healthcare and research.

The combination of precision medicine, cancer genomics, rare disease testing, pathogen surveillance, reproductive health, and population genomics provides multiple demand pathways. The market's evolution will increasingly depend on the ability of providers to connect sequencing technology with interpretation, clinical workflows, and actionable insights.

Competition is likely to intensify as established companies expand installed platforms while emerging players introduce alternative sequencing technologies. Cost per sample, accuracy, turnaround time, scalability, workflow simplicity, and analytics will remain important areas of differentiation.

Market Segmentation

The market can be segmented by product and service, technology, workflow, application, end user, and region.

By product and service, segments include instruments/systems, consumables and reagents, software and data analytics, and services. By technology, the market includes next-generation sequencing, Sanger sequencing, PCR-based sequencing/detection, microarray technology, nanopore sequencing, and other technologies.

By application, major segments include infectious disease surveillance, oncology, genetic and rare disease testing, reproductive health, agricultural and environmental genomics, and forensic genomics.

By end user, the market covers hospitals and diagnostic laboratories, academic and research institutes, pharmaceutical and biotechnology companies, government and public-health agencies, and contract research organizations.

Regionally, the market spans North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=86982<ype=S

Important FAQs with Answers

What is the genomic surveillance/sequencing market size in 2025?

The market was valued at USD 13.8 billion in 2025.

What will the market be worth by 2036?

It is projected to reach USD 74.1 billion by 2036.

What is the expected market CAGR?

The market is projected to expand at a 16.5% CAGR from 2026 to 2036.

Which segment led the market in 2025?

Consumables and reagents held the largest product and service share, at approximately 48.9%.

Which region dominated the market?

North America accounted for the largest revenue share, at approximately 46.3% in 2025.

More Trending Reports by Transparency Market Research –

Next Generation Sequencers (NGS) Market: https://www.transparencymarketresearch.com/next-generation-sequencers-market.html

Connected Medical Devices Market: https://www.transparencymarketresearch.com/connected-medical-devices-market.html

Internet of Medical Things Market: https://www.transparencymarketresearch.com/internet-of-medical-things-iomt-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com